Nuvation Bio: FDA accepts NDA for taletrectinib, sets PDUFA date
The FDA has accepted Nuvation Bio's NDA for taletrectinib to treat advanced ROS1-positive NSCLC, with a PDUFA date set for June 23, 2025
Read full article »
Nuvation Bio is a New York-based biotechnology company that researches and develops novel therapeutics for the treatment of cancer.
Read more